Full Name
Jianbiao Zhou
Variants
Zhou J.
Zhou, J.
Zhou, J.B.
Zhou J
Zhou Jianbiao
Zhou, Jianbiao
 
 
 
Email
csizjb@nus.edu.sg
 

Publications

Refined By:
Department:  MEDICINE
Department:  CANCER SCIENCE INSTITUTE OF SINGAPORE
Author:  Albert, D.H.

Results 1-8 of 8 (Search time: 0.004 seconds).

Issue DateTitleAuthor(s)
12008ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograftJasinghe, V.J. ; Xie, Z. ; Zhou, J. ; Khng, J.; Poon, L.-F. ; Senthilnathan, P. ; Chen, C.-S. ; Albert, D.H.; Davidsen, S.K.
22009ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedsideZhou, J. ; Chen, C.-S. ; Goh, B.-C.; Albert, D.H.
32009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J.; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
42009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
52008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J.; Bi, C.; Poon, L.F.; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
62008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
72008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J. ; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
8Jan-2008Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathwayZhou, J. ; Pan, M.; Xie, Z. ; Loh, S.-L.; Bi, C.; Tai, Y.-C.; Lilly, M.; Lim, Y.-P. ; Han, J.-H.; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.; Chen, C.-S.